These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 3265956)

  • 1. Incidence and management of diarrhea during longterm auranofin therapy.
    Wallin BA; McCafferty JP; Fox MJ; Cooper DR; Goldschmidt MS
    J Rheumatol; 1988 Dec; 15(12):1755-8. PubMed ID: 3265956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loose stools during auranofin treatment: clinical study and some pathogenetic possibilities.
    van Riel PL; Gribnau FW; van de Putte LB; Yap SH
    J Rheumatol; 1983 Apr; 10(2):222-6. PubMed ID: 6408256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmarketing experience with auranofin in the Federal Republic of Germany.
    Schattenkirchner M; Missler B; Mulz D
    Scand J Rheumatol Suppl; 1986; 63():57-66. PubMed ID: 3299683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of auranofin as demonstrated by improvement in clinical parameters and decrease in anti-inflammatory usage: a long-term, multicenter study.
    Brenol JC; Chahade W; De Freitas GG; De Pádua PM; Rachid A; Samara A; Seda H; Ximenes AC
    Scand J Rheumatol Suppl; 1986; 63():37-45. PubMed ID: 3299682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of auranofin: a review of clinical experience.
    Blodgett RC; Pietrusko RG
    Scand J Rheumatol Suppl; 1986; 63():67-78. PubMed ID: 3110943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose response studies and longterm evaluation of auranofin in rheumatoid arthritis.
    Champion GD; Cairns DR; Bieri D; Adena MA; Browne CD; Cohen ML; Day RO; Edmonds JP; Graham GG; de Jager J
    J Rheumatol; 1988 Jan; 15(1):28-34. PubMed ID: 3280795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prospective clinical study of the combination therapy of auranofin and methotrexate for rheumatoid arthritis--a multi-center study].
    Kashiwazaki S; Akizuki M; Ichikawa Y; Uchida S; Kondo H; Torikai K; Hayashi T; Hara M; Matsuoka Y
    Ryumachi; 1996 Jun; 36(3):528-44. PubMed ID: 8779790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Auranofin: first choice for remission-inducing drug (RID) therapy in rheumatoid arthritis?
    Bandilla K; Missler B; Klein-Reesink B
    Scand J Rheumatol Suppl; 1986; 63():47-54. PubMed ID: 3474777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longterm auranofin therapy in patients with juvenile rheumatoid arthritis.
    Giannini EH; Brewer EJ; Person DA; He XH
    J Rheumatol; 1986 Aug; 13(4):768-70. PubMed ID: 3534260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical effectiveness and tolerance of auranofin in patients with chronic polyarthritis. Results of a multicenter long-term study].
    Klein G; Schwann H; Mirtl B; Thumb N; Mayerhofer F; Singer F; Tausch G; Gaismayer K; Rieder H; Hartweger A
    Z Rheumatol; 1988; 47(5):342-6. PubMed ID: 3149087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Auranofin therapy in juvenile rheumatoid arthritis: a 48-week phase II study.
    Kvien TK; Høyeraal HM; Sandstad B; Kass E
    Scand J Rheumatol Suppl; 1986; 63():79-83. PubMed ID: 3474778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open study on the efficacy and safety of auranofin in treating psoriatic arthritis.
    Dequeker J; Gevers G
    Scand J Rheumatol Suppl; 1986; 63():85-95. PubMed ID: 3474779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The moderate intestinal side effects of auranofin do not require prophylactic therapy with a bulkforming agent. Dutch Ridaura Study Group.
    van Beusekom HJ; van de Laar MA; Franssen MJ; van Valburg JA; Gijzel WP; Couvée JE
    Clin Rheumatol; 1997 Sep; 16(5):471-6. PubMed ID: 9348142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study on combined of auranofin, salazosulfapyridine and methotrexate in rheumatoid arthritis].
    Fujii T; Suwa A; Yosida T; Mimori T; Akizuki M
    Ryumachi; 1994 Jun; 34(3):571-82. PubMed ID: 7914383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind study comparing sodium aurothiomalate and auranofin in patients with rheumatoid arthritis previously stabilized on sodium aurothiomalate.
    Hull RG; Morgan SH; Parke AL; Childs L; Goldman M; Hughes GR
    Int J Clin Pharmacol Res; 1984; 4(6):395-401. PubMed ID: 6442711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gold therapy in rheumatoid arthritis. Interim report of the Canadian multicenter prospective trial comparing sodium aurothiomalate and auranofin.
    Menard HA; Beaudet F; Davis P; Harth M; Percy JS; Russell AS; Thompson JM
    J Rheumatol Suppl; 1982; 8():179-83. PubMed ID: 6813482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of rheumatoid arthritis complicated with auranofin-induced acute interstitial pneumonitis].
    Okuda Y; Takasugi K; Imai A; Hasimoto F; Kondo Y; Hatinota M; Ueda S; Nitta M
    Ryumachi; 1991 Feb; 31(1):54-61; discussion 59-60. PubMed ID: 1857997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group.
    Kalden JR; Scott DL; Smolen JS; Schattenkirchner M; Rozman B; Williams BD; Kvien TK; Jones P; Williams RB; Oed C; Rosenburg R;
    J Rheumatol; 2001 Sep; 28(9):1983-91. PubMed ID: 11550964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study.
    Borg G; Allander E; Lund B; Berg E; Brodin U; Pettersson H; Trang L
    J Rheumatol; 1988 Dec; 15(12):1747-54. PubMed ID: 14552308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gynecomastia as a complication of auranofin therapy.
    Williams HJ
    J Rheumatol; 1988 Dec; 15(12):1863-4. PubMed ID: 3230571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.